Oncorus to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 07:00 ET
|
Oncorus, Inc.
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today...
Oncorus Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 04, 2022 07:00 ET
|
Oncorus, Inc.
Additional clinical data from ONCR-177 surface lesion monotherapy and combination expansion cohorts expected in second half of 2022Company remains on track to submit IND for ONCR-021 in mid-2023Ended...
Oncorus Appoints Douglas Fambrough to Board of Directors
June 23, 2022 07:00 ET
|
Oncorus, Inc.
-Former CEO of Dicerna brings deep expertise in RNA research, drug development, business development and financing- CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq:...
Oncorus to Present at the Jefferies Global Healthcare Conference
June 01, 2022 07:00 ET
|
Oncorus, Inc.
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today...
Oncorus to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022 07:00 ET
|
Oncorus, Inc.
CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today...
Oncorus Announces Appointment of Richard Wanstall as Chief Financial Officer
May 10, 2022 07:00 ET
|
Oncorus, Inc.
CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, today...
Oncorus Reports First Quarter 2022 Financial Results and Provides Business Updates
May 04, 2022 07:00 ET
|
Oncorus, Inc.
Additional clinical data from ONCR-177 surface lesion monotherapy expansion and combination expansion cohorts expected in second half of 2022Preclinical data presented for ONCR-021 and ONCR-788 at...
Oncorus Presents Preclinical Data on ONCR-021 and ONCR-788 Supporting Selectively Self-Amplifying vRNA Immunotherapy Platform at AACR Annual Meeting
April 08, 2022 13:00 ET
|
Oncorus, Inc.
– ONCR-021 and ONCR-788 demonstrate robust preclinical anti-tumor efficacy following IV-administration – – vRNA Immunotherapy Platform has the potential to address challenges associated with...
Oncorus Announces Debt Capital Facility with K2 HealthVentures with $20 Million Funded at Closing, Relocation of Corporate Headquarters and Extension of Cash Runway
April 05, 2022 07:00 ET
|
Oncorus, Inc.
-Multiple tranche debt financing agreement provides Oncorus with access to up to $45 million- -Use of proceeds intended to support completion of a GMP-compliant manufacturing facility in Andover, MA...
Oncorus to Present at the Maxim Group 2022 Virtual Growth Conference
March 21, 2022 07:00 ET
|
Oncorus, Inc.
CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today...